Burger King Colombia has partnered with Chilean plant-based company NotCo to offer flexitarians the Veggie Whopper, King Veggie, and Nuggets Veggie.
The deal helps expand the plant-based movement across Latin America.
Using the slogan “We declare ourselves Flexitarians!”, Burger King is promoting the new options as 100 percent plant-based, although it’s yet unspecified if the bread and sauces are vegan.
Meanwhile, in announcing the new veggie line from Burger King on social media, NotCo insists that “more and more people believe that removing animals from the equation is the answer for a more sustainable yet equally delicious world.”
NotCo has partnered with Burger King Chile to launch plant-based chicken sandwiches and nuggets, with BK Peru to bring its plant-based burger patties to the country, and with Starbucks Mexico in introducing its plant-based NotChicken Baguette and NotBurger Baguette.


U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
The American mass exodus to Canada amid Trump 2.0 has yet to materialize
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall
Youth are charting new freshwater futures by learning from the water on the water
Can your cat recognise you by scent? New study shows it’s likely
Debate over H-1B visas shines spotlight on US tech worker shortages
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 



